Skip to main content
. 2019 Sep 14;8(9):1463. doi: 10.3390/jcm8091463

Table 3.

Concentrations of serum acylcarnitines and hexoses of the study subjects. Data are shown as mean ± standard error (μmol/L).

Non-PAD Control (n = 26) IC (n = 26) CLI (n = 26) p
Acylcarnitine 43.5 ± 2.1 40.6 ± 2.1 31.1 ± 2.2 *,† 0.001
Acetyl-L-carnitine 8.7 ± 1.0 9.5 ± 1.1 9.6 ± 1.1 0.816
Propionylcarnitine 0.351 ± 0.038 0.391 ± 0.037 0.294 ± 0.039 0.221
Malonylcarnitine 0.006 ± 0.001 0.006 ± 0.001 0.007 ± 0.001 0.452
Hydroxypropionylcarnitine 0.040 ± 0.002 0.046 ± 0.002 * 0.047 ± 0.002 * 0.003
Propenoylcarnitine 0.017 ± 0.001 0.019 ± 0.001 * 0.019 ± 0.001 * 0.050
Butyrylcarnitine 0.169 ± 0.023 0.168 ± 0.023 0.153 ± 0.024 0.869
Hydroxybutyrylcarnitine 0.055 ± 0.015 0.093 ± 0.015 0.084 ± 0.016 0.189
Butenylcarnitine 0.030 ± 0.001 0.030 ± 0.001 0.029 ± 0.001 0.879
Isovalerylcarnitine 0.086 ± 0.01 0.092 ± 0.01 0.066 ± 0.01 0.189
Tiglylcarnitine 0.023 ± 0.01 0.025 ± 0.01 * 0.026 ± 0.01 * 0.038
Hexoses 5266 ± 489 6034 ± 479 5967 ± 508 0.476

Note: The values presented in the column “p-value” represent the overall difference between the three groups; bold font indicates a significant difference between groups (p < 0.05); post-hoc differences in comparisons between individual groups are denoted below as * = significant difference from non-PAD control, p < 0.05; † = significant difference from IC, p < 0.05.